Tweet
<img alt="" height="1" width="1" />
Medivation, Pfizer drug fails Alzheimer's study
Reuters
NEW YORK, March 3 (Reuters) - Medivation Inc (MDVN.O) and Pfizer (PFE.N) said on Wednesday their experimental drug, Dimebon, failed to meet the main goals in a highly anticipated late-stage clinical trial for Alzheimer's disease. ...
Pfizer Alzheimer's disease drug fails in studyThe Associated Press
Pfizer, Medivation's Dimebon Fails to Help Alzheimer's PatientsBusinessWeek
BREAKING NEWS: Medivation's Dimebon fails Phase III for Alzheimer'sFierceBiotech
TheStreet.com -MarketWatch -Bizjournals.com
all 26 news articles »
More...